Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genor Biopharma Holdings Limited (6998.HK)
Shanghai, CN
Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally. Its key investigational medicines include GB242, an infliximab (Remicade) biosimilar. This drug is purposed for the treatment of various conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric Crohn's disease, and fistulizing Crohn's disease. Another prominent candidate is GB491 (lerociclib), an oral CDK4/6 inhibitor currently undergoing Phase III clinical trials for hormone receptor-positive (HR+)/HER2- breast cancer. Additionally, GB492, a stimulator of interferon genes (STING) agonist, is in Phase 1/2 clinical development, with expectations of synergistic effects when combined with GB226 for solid tumor treatment. The company's pipeline also encompasses GB221, a HER2 monoclonal antibody (mAb) designed to mimic trastuzumab (Herceptin); geptanolimab (GB226), a novel PD-1 mAb; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb, which is in Phase I clinical trials; and GB261, also in Phase I clinical trials for B-cell non-Hodgkin Lymphoma. Furthermore, its product candidates in clinical trials for cancer treatment include GB262, GB264, GB265, and GB266. Originally named JHBP (CY) Holdings Limited, the company adopted its current moniker, Genor Biopharma Holdings Limited, in June 2021. Founded in 2007, the firm maintains its headquarters in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.56% | -5.21% | -34.43% | -28.83% | -42.20% | -33.33% | -25.65% | +14.29% | -88.18% | -92.84% | -92.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+1,075.0% ★
-
EPS growth Biotechnology: +29.7%+320.2% ★ Q4'25: +141.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+11.6% Q4'25: +10.7% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+25.6% ★ Q4'25: +19.1% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+11.6% ★ Q4'25: +35.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+230.8% Q4'25: +163.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.60× Q4'25: 0.48× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|
| Revenue |
—
est: 10.02M (-100.0%)
|
15.93M
est: 9.94M (+60.3%)
|
—
est: 9.96M (-100.0%)
|
206.23M
est: 47.66M (+332.7%)
|
2.42B
est: 326.59M (+641.9%)
|
| EBITDA |
-840.19M
est: -50.0K (-1,679,637.7%)
|
-675.89M
est: -49.6K (-1,361,312.8%)
|
-551.01M
est: -49.8K (-1,107,295.9%)
|
-5.15M
est: 12.95M (-139.8%)
|
929.10M
est: 88.73M (+947.1%)
|
| EBIT |
-884.20M
est: -684.1K (-129,148.1%)
|
-729.56M
est: -679.0K (-107,347.9%)
|
-616.29M
est: -680.5K (-90,462.9%)
|
-70.44M
est: 8.71M (-908.4%)
|
619.27M
est: 59.70M (+937.3%)
|
| Net Income |
-865.37M
est: -1.29B (+33.0%)
|
-730.40M
est: -663.62M (-10.1%)
|
-674.36M
est: -526.97M (-28.0%)
|
-51.28M
est: -1.31B (+96.1%)
|
388.93M
est: -628.26M (+161.9%)
|
| SGA |
305.95M
est: 78.83M (+288.1%)
|
217.27M
est: 78.24M (+177.7%)
|
125.24M
est: 78.42M (+59.7%)
|
71.71M
est: 154.64M (-53.6%)
|
573.73M
est: 1.06B (-45.9%)
|
| EPS |
-1.75
est: -2.51 (+30.4%)
|
-1.45
est: -1.29 (-12.2%)
|
-1.33
est: -1.03 (-29.6%)
|
-0.10
est: -0.77 (+87.0%)
|
0.23
est: -0.37 (+162.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Xin Ni | Chief Executive Officer & Executive Chairman | 6M | male |
| Chui Mei Yip | Joint Company Secretary | — | female |
| Feng Guo | Chief Executive Officer | — | — |
| Hanqing Xie | Senior Vice President | — | female |
| Qianhui Wang | Joint Company Secretary | — | female |
| Shuhua Han | Chief Scientific Officer & Executive Director | — | — |
| Chen Zi | Executive Vice President | — | male |
| Zhibing Weng | Senior Vice President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6998.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
